Table 1 Baseline clinical and demographic characteristics of patients with rheumatoid arthritis were included in the cross-sectional analysis
RA cohort treated with b/tsDMARDs (N = 610) | |
|---|---|
Demographic | |
Age (years) mean ± SD | 58.1 ± 12.5 |
Female, (n, %) | 507 (83.1%) |
BMI (median, IQR) | 23 (21 – 26) |
Current Smokers (n, %) | 115 (18.9%) |
Disease characteristics | |
RF and/or ACPA positive, (n, %) | 387 (66.6%) |
Disease duration (years) mean ± SD | 17.4 ± 11.7 |
PGA 0–10 (median, IQR) | 3 (1 – 5) |
NRS 0–10 (median, IQR) | 3 (0 – 5) |
PhGA 0 -10 (median, IQR) | 0 (0 – 1) |
CRP (mg/dL) (median, IQR) | 0.18 (0.07 – 0.5) |
SDAI mean ± SD | 8.2 ± 7.1 |
HAQ (median, IQR) | 0.375 (0.125 – 0.75) |
Time-to-biologic (months) mean ± SD | 98.1 ± 91.9 |
Time-to-refractory (months) mean ± SD | 77.3 ± 54.1 |
Selected comorbidities | |
Osteoarthritis (n, %) | 296 (48.5%) |
Fibromyalgia (n, %) | 55 (9%) |
CCI (median, IQR) | 2 (1 – 3) |
Current therapy | |
Mechanism of action, n (%) | |
TNFα inhibitors | 291 (47.7%) |
IL-6 inhibitors | 90 (14.8%) |
Anti-CD20 | 40 (6.6%) |
Anti-CTLA4 | 80 (13.1%) |
JAK inhibitors | 108 (17.7%) |
IL-1 inhibitors | 1 (0.1%) |
b/tsDMARDs line (median, IQR) | 1 (1 – 2) |
csDMARDs (n, %) | 307 (50.3%) |
Glucocorticoids (n, %) | 214 (35.1%) |
Low dose glucocorticoids (n, %) | 138 (22.6%) |
NSAIDs (n, %) | 171 (28%) |
Analgesic use (n,%) | 90 (14.8%) |